Ethical considerations in the marketing of e-health products

Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing

Volumn 4, Issue 2, 2004, Pages 110-118

  Chandra, Ashish ^a   Sikula, Andrew ^b   Paul, David P ^b  

^a Marshall University Graduate College   (United States)

^b NONE

Author keywords

alternative medicine; e health; ethics; online healthcare marketers; online pharmaceutical marketers

Indexed keywords

EID: 84990365187     PISSN: 17457904     EISSN: 17457912     Source Type: Journal    
DOI: 10.1057/palgrave.jmm.5040152     Document Type: Article

References (61)

1. Kotler P. (2003) Marketing Management, 11th edn., Prentice Hall, Upper Saddle River.
2. Kalin S. (1999) ‘Choose your medicine’, CIO Web Business Magazine, http://www.cio.com/archive/webbusiness/060199_drugs.html pp. 1–8.
3. Leckenby J.D. Hong J. (1998) ‘Using reach/frequency for web media planning’, Journal of Advertising Research, 38(1), 7–20.
4. Anonymous (2003) ‘Internet usage on the rise, with more consumers logging on daily’, 2 July, www.consumerinterestbarometer.us/press.htm.
5. Goldhagen H. (1998) ‘This is medicine? Alternative medicine web sites’, Infectious Medicine, 15(5), 309–313.
6. DeLuca J.H. Enmark R. (2000) ‘E-health: The changing model of healthcare’, Frontiers of Health Services Management, 17(1), 3–15.
7. Chin R. (2000) ‘The internet: Another facet to the paradigm shift in healthcare’, Singapore Journal of Medicine, 41(9), 426–429.
8. Deluca J.H. Enmark R. (2001) ‘The latest revolution’, Health Forum Journal, 44(1), 22–25.
9. Sànchez A.O. Martin Fuentes M.T. (2002) ‘Consumer orientation of public hospital websites in Spain’, International Journal of Medical Marketing, 3(1), 20–30.
10. Landro L. (2000) ‘Web health groups ponder how to set universal standards’, New York Times (Eastern edn.) 2 November, B1.
11. Risk A. Dzenowagis J. (2001) ‘Review of internet health information quality initiatives’, Journal of Medical Internet Research, 3(4), 28.
12. Anonymous (2000) ‘Sizing healthcare eCommerce’, Forrester Research (January) http://www.forrester.com/.
13. Lomangina K. (1999) ‘Point and click prescriptions: Pros and cons of online pharmacies and guides for use’, Internet Medicine, 4(5), 1, 3, 4.
14. Weschler J. (2000) ‘Prices, promotion, politics’, Pharmaceutical Executive, 20(1), 24–30.
15. Gallanis P.J. (1999) ‘E-tailers and retailers work to concoct perfect prescription’, DSN Retailing Today, 38(23), p. 60.
16. Manhal-Baugus M. (2001) ‘E-therapy: Practical, ethical and legal issues’, Cyberpsychology & Behavior, 4(5), 551–563.
17. Chandra A. Pettry C.E. Jr Paul D.P. III (2004) ‘Telemedicine from a macromarketing viewpoint: A critical evaluation with proposed licensing strategies’, Journal of NonProfit and Public Sector Marketing, forthcoming.
18. Mack J. (2000) ‘You have a brochure on the web. Now what?’, Pharmaceutical Executive, March, 16–22.
19. Anonymous (2000) ‘Internet code of ethics’, Trustee 53(7), 4, 6.
20. Liebman M. (2002) ‘For online privacy compliance, HIPAA rules’, Medical Marketing & Media, May, 100–106.
21. Fried B.M. Weinreich G. Cavelier G.M. Lester K.J. (2000) ‘E-health: Technology revolution meets regulatory constraint’, Health Affairs, 19(6), 124–131.
22. Deluca J.H. Enmark R. (2001) Health Affairs
23. Goldman J. Hudson Z. (2000) ‘Virtually exposed: Privacy and e-health’, Health Affairs, 19(6), 140–148.
24. Liebman M. (2000) ‘Down-to-earth internet ethics codes set standards for cyberspace’, Medical Marketing & Media, June, 100–102.
25. Mack J. (2000) Medical Marketing & Media
26. Adams M. (2002) ‘Gaining trust, protecting privacy’, Pharmaceutical Executive, December, 46–49.
27. Deluca J.H. Enmark R. (2001) Pharmaceutical Executive
28. Fried B.M. (2000) Pharmaceutical Executive
29. Liebman M. (2000) Pharmaceutical Executive
30. Weschler J. (2001) ‘Setting eHealth standards is top-of-mind for MCOs’, Managed Healthcare Executive, 11(3), 47, 49–50.
31. Fried B.M. (2000) Managed Healthcare Executive
32. Hagerty J.R. Berman D.K. (2003) ‘New battleground in web privacy war: Ads that snoop’, Wall Street Journal, 27 August, A1, A8.
33. Fried B.M. (2000) Wall Street Journal
34. Weschler J. (2001) Wall Street Journal
35. Boulding M.E. (2000) ‘Self-regulation: Who needs it?’, Health Affairs, 19(6), 132–139.
36. Peeples D.K. (2002) ‘Instilling consumer confidence in e-commerce’, S.A.M. Advanced Management Journal, 67(4), 26–31.
37. Adams M. (2002) S.A.M. Advanced Management Journal
38. Marshall K.P. (1999) ‘Has technology introduced new ethical problems?’, Journal of Business Ethics, 19(1), 81–90.
39. Crabtree P. Dibble S. (2003) ‘Tijuana alternative clinics frustrate regulators’, San-Diego Tribune, 24 February, A1.
40. Gillis J. (2003) ‘A rush of products ready (or not) to fight SARS’, Washington Post, 10 May, E01.
41. Weschler J. (2000) Washington Post
42. Gritzmacher D. Broussard A. Cody D. (2003) ‘The new realities of money and politics in complementary/alternative medicine’, Business and Health Administration Association Proceedings, 153–158.
43. Kanter L. (1999) ‘Natural cures: Herbs are huge, but do they work?’ Los Angeles Business Journal, 18 January, 2.
44. Razzouk N. Seitz V. Luus S.P. (2002) ‘Quackery in healthcare: Implications for marketers’, From Art to Technology: Opportunities in Marketing Research and Education, Atlantic Marketing Association Proceedings, 30–33.
45. West D.J. Jr (2003) ‘Integrative healthcare at inner harmony: The convergence of Eastern and Western thinking about health’, Business and Health Administration Association Conference Proceedings, 333–337.
46. Kearney A.T. (1997) Maximizing Health in the Next Millennium: A Prescription for Increased Shareholder Value, Kearney, Chicago.
47. Frank R.G. (2003) ‘Government commitment and regulation of prescription drugs’, Health Affairs, 22(3), 46–48.
48. Iglehart J.K. (2003) ‘Good science and the marketplace for drugs: A conversation with Jean-Pierre Garnier’, Health Affairs, 22(4), 119–127.
49. Health Affairs.
50. Eagle L. Kitchen P. (2002) ‘Direct consumer promotion of prescription drugs: A review of the literature and the New Zealand experience’, International Journal of Medical Marketing, 2(4), 293–310.
51. Applequist K. (1999) ‘OnlineDrugs.com: Legal issues raised by online pharmacies’, Drug Benefit Trends, 11(5), 28, 37.
52. Attas D. (1999) ‘What's wrong with ‘deceptive’ advertising?’, Journal of Business Ethics, 21(1), 49–59.
53. Kahn C. (2001) ‘How the media influences women's perceptions of healthcare’, Marketing Health Services, 21(1), 13–17.
54. Sibley C.E. (2000) ‘Scattershot studies, self-serving sponsors: Can't we get better DTC advertising research?’, Medical Marketing & Media, 35(2), 96–98, 100.
55. Fischman J. Melton M. (1999) ‘Drug bazaar’, US News & World Report, 126(24), 58.
56. Basara L.R. Juergens J.P. (1994) ‘Patient package insert readability and design’, American Pharmacy, August, 48–53.
57. Edwards S.M. Li H. Lee J-H (2002) ‘Forced exposure and psychological reactance: Antecedents and consequences of the perceived intrusiveness of pop-up ads’, Journal of Advertising, 31(3), 83–92.
58. Liu Y. Shrum L.J. (2002) ‘What is interactivity and is it always a good thing? implications of definition, person and situation for the influence of interactivity on advertising effectiveness’, Journal of Advertising, 31(4), 53–64.
59. Stern B.B. Zinkham G.M. Holbrook M.B. (2002) ‘Netvertising image communication model (NICM) and construct definition’, Journal of Advertising, 31(3), 15–27.
60. Liebman M. (2000) Journal of Advertising
61. Fisher S.E. (2000) ‘Online healthcare contends with fraud’, InfoWorld, 22, 27.